Cobblestone Capital Advisors LLC NY Buys 3,552 Shares of Pfizer Inc. $PFE

Cobblestone Capital Advisors LLC NY increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 43,653 shares of the biopharmaceutical company’s stock after buying an additional 3,552 shares during the period. Cobblestone Capital Advisors LLC NY’s holdings in Pfizer were worth $1,058,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC grew its position in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley cut their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.79 on Monday. The company has a 50 day moving average of $24.87 and a 200-day moving average of $24.20. The company has a market cap of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.